AU2003262805A1 - Acetophenone potentiators of metabotropic glutamate receptors - Google Patents

Acetophenone potentiators of metabotropic glutamate receptors Download PDF

Info

Publication number
AU2003262805A1
AU2003262805A1 AU2003262805A AU2003262805A AU2003262805A1 AU 2003262805 A1 AU2003262805 A1 AU 2003262805A1 AU 2003262805 A AU2003262805 A AU 2003262805A AU 2003262805 A AU2003262805 A AU 2003262805A AU 2003262805 A1 AU2003262805 A1 AU 2003262805A1
Authority
AU
Australia
Prior art keywords
compound
phenyl
pct
6alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003262805A
Other languages
English (en)
Inventor
Rowena V. Cube
Anthony B. Pinkerton
Jean-Michel Vernier
Xiumin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2003262805A1 publication Critical patent/AU2003262805A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003262805A 2002-08-26 2003-08-22 Acetophenone potentiators of metabotropic glutamate receptors Abandoned AU2003262805A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40590802P 2002-08-26 2002-08-26
US60/405,908 2002-08-26
PCT/US2003/026377 WO2004018386A2 (en) 2002-08-26 2003-08-22 Acetophenone potentiators of metabotropic glutamate receptors

Publications (1)

Publication Number Publication Date
AU2003262805A1 true AU2003262805A1 (en) 2004-03-11

Family

ID=31946942

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003262805A Abandoned AU2003262805A1 (en) 2002-08-26 2003-08-22 Acetophenone potentiators of metabotropic glutamate receptors

Country Status (6)

Country Link
US (1) US20050288346A1 (enExample)
EP (1) EP1556038A2 (enExample)
JP (1) JP2006502143A (enExample)
AU (1) AU2003262805A1 (enExample)
CA (1) CA2495756A1 (enExample)
WO (1) WO2004018386A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2006003700A0 (en) 2004-02-13 2006-08-31 Warner Lambert Co Androgen receptor modulators
WO2005100305A1 (en) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
CA2562672C (en) * 2004-04-22 2009-09-29 Warner-Lambert Company Llc 4-cyano-phenoxy derivatives as androgen modulators
JP4874965B2 (ja) 2004-07-08 2012-02-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲン調節剤
CA2574956A1 (en) * 2004-07-30 2006-02-09 Merck & Co., Inc. Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2011226942B2 (en) * 2004-11-22 2012-06-28 Eli Lilly And Company Potentiators of glutamate receptors
AU2005309855B2 (en) * 2004-11-22 2011-10-06 Eli Lilly And Company Potentiators of glutamate receptors
WO2006091496A2 (en) * 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900391A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
TW200900065A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
US8722894B2 (en) * 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
MX2010002536A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetrahidro-2h, 1'h-[1,4]bipiridinil-2'-onas 1',3'-disubstituidas.
TW201006801A (en) * 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
CA2744138C (en) 2008-11-28 2015-08-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
ES2409006T3 (es) 2009-05-12 2013-06-24 Janssen Pharmaceuticals Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
WO2012007869A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PT3096790T (pt) 2014-01-21 2019-10-15 Janssen Pharmaceutica Nv Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso
EA202192105A3 (ru) 2014-02-04 2022-02-28 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
US10099993B2 (en) 2014-04-06 2018-10-16 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof
MX2021007377A (es) * 2018-12-17 2021-11-25 6Th Wave Innovations Corp Extraccion de litio con eteres de corona.
US20250179000A1 (en) * 2021-12-23 2025-06-05 Sanford Burnham Prebys Medical Discovery Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
EP4299124A1 (en) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2 nanobodies for use as biomolecule transporter

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2058785B (en) * 1979-09-05 1983-05-25 Glaxo Group Ltd Phenol derivatives
DE3116079A1 (de) * 1981-04-23 1982-11-11 Robert Bosch Gmbh, 7000 Stuttgart Pruefsystem
US4567201A (en) * 1981-11-25 1986-01-28 Takeda Chemical Industries, Ltd. Diphenoxypropane derivatives and compositions of antiasthmatic and antiinflammatory agents thereof
ES8505199A1 (es) * 1982-10-21 1985-05-16 Lilly Industries Ltd Un procedimiento para la preparacion de derivados de difenilalquilenicos.
US4820867A (en) * 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
GB8318889D0 (en) * 1983-07-13 1983-08-17 Lilly Industries Ltd Pharmaceutical compounds
US4663332A (en) * 1985-10-10 1987-05-05 Hoffman-La Roche Inc. 5-substituted N-alkylated tetrazoles
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states

Also Published As

Publication number Publication date
EP1556038A2 (en) 2005-07-27
JP2006502143A (ja) 2006-01-19
WO2004018386A2 (en) 2004-03-04
US20050288346A1 (en) 2005-12-29
CA2495756A1 (en) 2004-03-04
WO2004018386A3 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
AU2003262805A1 (en) Acetophenone potentiators of metabotropic glutamate receptors
US7960417B2 (en) Benzazole potentiators of metabotropic glutamate receptors
WO2006047237A2 (en) Heterocyclic indanone potentiators of metabotropic glutamate receptors
US20080312286A1 (en) Indanone Potentiators of Metabotropic Glutamate Receptors
JP2008508288A (ja) 代謝調節型グルタミン酸受容体のヘテロ環式アセトフェノン増強剤
CA2590349C (en) Potentiators of glutamate receptors
US7507836B2 (en) Benzamide modulators of metabotropic glutamate receptors
US20070287716A1 (en) Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors
US20110065669A1 (en) Oxazolobenzimidazole derivatives
DE69024843T2 (de) Rhodanin-Derivate und pharmazeutische Zusammensetzungen
CN101426786A (zh) 代谢型谷氨酸受体吲哚增强剂
EP0239533A1 (de) Pyridin-Derivate

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application